Hospital Mortality in Patients Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01791764|
Recruitment Status : Completed
First Posted : February 15, 2013
Last Update Posted : February 15, 2013
This study has the following objective:
To identify related factors to hospital mortality in patients with ST-segment elevation acute myocardial infarction submitted to pharmacoinvasive strategy within a structured healthcare network.
|Condition or disease|
|Acute Coronary Syndrome|
Primary percutaneous coronary intervention is the main therapy for patients with ST-segment elevation acute myocardial infarction. However, a significant portion of these patients won't receive optimal treatment due to the small number of tertiary centers with interventional laboratories available for 24 hours a day, 7 days a week.
Specially in large urban centers and rural areas, where tertiary care hospitals are restricted to a specific region, alternative approaches must be developed. The pharmacoinvasive strategy has emerged as an alternative for patients admitted to primary care centers. It is based in up-front intravenous thrombolytic therapy and transfer to a tertiary center where early, systematic, coronary intervention will be performed between 3 to 24 hours after the administration of thrombolytic drugs, even in cases in which successful reperfusion was obtained.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||368 participants|
|Target Follow-Up Duration:||15 Days|
|Official Title:||Hospital Mortality After ST Segment Elevation Acute Myocardial Infarction Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK): Analysis of 398 Patients.|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||October 2012|
|Actual Study Completion Date :||October 2012|
- Hospital Mortality [ Time Frame: During hospital stay,an expected average of 15 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01791764
|Federal University of Sao Paulo|
|Sao Paulo, SP, Brazil|
|Principal Investigator:||Felipe JA Falcao||Federal University of Sao Paulo|
|Principal Investigator:||Claudia MR Alves, Doctor||Federal University of Sao Paulo|
|Study Director:||Antonio CC Carvalho||Federal University of Sao Paulo|
|Study Director:||Adriano HP Barbosa||Federal University of Sao Paulo|